-
Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter and Symplicity G3™ Renal Denervation RF Generator Approved for Marketing
2024-04-30
Recently, the innovative products Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter and Symplicity G3™ Renal Denervation RF Generator of Medtronic, Inc. were approved by China NMPA.
-
Entinostat Tablets Approved for Marketing by China NMPA
2024-04-30
Recently, the Category I innovative drug Entinostat Tablets (Chinese trade name: 景助达) of Taizhou EOC Pharma Co. Ltd was approved for marketing by the National Medical Products Administration.
-
Iptacopan Hydrochloride Capsules Approved for Marketing by China NMPA
2024-04-30
Recently, the Category I innovative drug Iptacopan Hydrochloride Capsules (trade name: FABHALTA) of Novartis Pharma Schweiz AG was approved for marketing by the National Medical Products Administration with priority review and approval, which is applicable for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.
-
MoyoAssist® Extracorporeal Ventricular Assist Device and Extracorporeal Ventricular Assist Pump Head and Circuit Approved for Marketing
2024-04-28
Recently, the innovative products MoyoAssist® Extracorporeal Ventricular Assist Device and Extracorporeal Ventricular Assist Pump Head and Circuit of magAssist Inc. (Suzhou) were approved for marketing.
-
Oligosaccharide Chain Detection Kit (Fluorophore-Assisted Carbohydrate Electrophoresis) Approved
2024-04-11
Recently, the innovative product Oligosaccharide Chain Detection Kit (Fluorophore-Assisted Carbohydrate Electrophoresis) of Jiangsu SysDiagno Biotech Co., Ltd. was approved by China NMPA.
-
Combined Glucometer Approved for Marketing
2024-04-11
Recently, the innovative product Combined Glucometer of Hangzhou Jingce Medical Technology Co., Ltd. was approved by China NMPA.
